Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Study P05495)
Brief Summary: This is a response-driven study of tildrakuzumab for the treatment of moderate to severe chronic plaque psoriasis. The primary study hypothesis is that one or more doses of tildrakizumab will be superior to placebo for the treatment of psoriasis.


Options:
A: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Matching Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab 200 mg, Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Placebo, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg
B: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
C: Arm Label: ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab 45 mg, ustekinumab 90 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Part 1: Tildrakizumab 5 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 25 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 2: Tildrakizumab 5 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 25 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 3: Tildrakizumab 5 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 25 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 100 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 200 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Placebo Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: tildrakizumab; Assigned to Arm(s): Part 1: Tildrakizumab 100 mg, Part 1: Tildrakizumab 200 mg, Part 1: Tildrakizumab 25 mg, Part 1: Tildrakizumab 5 mg, Part 2: Tildrakizumab 100 mg, Part 2: Tildrakizumab 200 mg, Part 2: Tildrakizumab 25 mg, Part 2: Tildrakizumab 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 1: Placebo

Answer: D